Welcome to Inflection Biosciences

Inflection Biosciences is developing small molecule therapeutics for the treatment of cancer. The pipeline includes first-in-class IBL-202, a dual PIM and PI3K inhibitor in development for B-cell malignancies. The IBL-100s comprises selective pan-PIM kinase inhibitors. The partnered pipeline comprises AUM302, being developed by AUM Biosciences. 

Addressing Unmet Needs

Cancer continues to be a major threat to human health globally. While progress has been made, much more needs to be achieved to provide better treatment solutions for patients. Our research and development focus targets major unmet medical needs in cancer.




Search - Use spaces to separate your keywords
Inflection Biosciences. Suite 15, Anglesea House Carysfort Avenue, Blackrock,  Co. Dublin.  

 Company registration no. 509046.

© 2020 Inflection Biosciences.   Web Design by Webtrade